Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: Individual patient data meta-analysis of randomized trials

Japanese Journal of Clinical Oncology

Volumn 29, Issue 2, 1999, Pages 78-86

  Sakamoto, Junichi ^a,e   Hamada, Chikuma ^b   Kodaira, Susumu ^c   Nakazato, Hiroaki ^d   Ohashi, Yasuo ^b  

^a AICHI PREFECTURAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d Yokoyama Gastrointestinal Hospital   (Japan)

^e AICHI PREFECTURAL UNIVERSITY   (Japan)

Author keywords

5 fluorouracil prodrugs; Adjuvant chemotherapy; Colorectal cancer; Meta analysis; Oral 5 fluorouracil; Randomized clinical trials

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; MITOMYCIN;

ADJUVANT CHEMOTHERAPY; ARTICLE; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; HUMAN; META ANALYSIS; MORTALITY; ORAL DRUG ADMINISTRATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RECTUM TUMOR; SURVIVAL RATE; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FLUOROURACIL; HUMANS; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RECTAL NEOPLASMS; SURVIVAL RATE;

EID: 0033070422     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/29.2.78     Document Type: Article

References (22)

1. Research Group for Population-based Cancer Registration in Japan. Cancer incidence in Japan, 1985-89: re-estimation based on data from eight population-based cancer registries. Jpn J Clin Oncol 1998;28:54-67.
2. Statistics and Information Department, Ministry of Health and Welfare. Deaths and death rates by sex and causes of death: Japan 1995 and 1994. In: Vital Statistics of Japan, vol 1, Health and Welfare Statistics Association, Tokyo, 1996;465.
3. Vernaba AM, Longo WE, Virgo KS, Coplin MA, Wade TP, Johnson FE. Current follow up statistics after resection of colorectal cancer. Dis Colon Rectum 1994;37:573-83.
4. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1991;41:19-51.
5. Freiman JA, Chalmers TC, Smith H, Kuebler RK. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 'negative' trials. N. Engl J Med 1978;299:690-4.
6. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med 1984;3:409-20.
7. Gorge SL. The required sample size and length of a phase III clinical trial. In: Buyse M, Staquet M, Sylvester R, editors. Cancer Clinical Trials: Methods and Practice. Oxford: Oxford University Press 1984;287-310.
8. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don't know. J Am Med Assoc 1988;259:3571-8.
9. Early Breast Cancer Trialists Collabroative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immue therapy. Lancet 1992;339:1-15.
10. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by surgical or radiological therapy. Lancet 1992;339:71-85.
11. Matsuda T, Yasutomi M, Kikuchi K, Kasai Y, Abe O, Kondo T, et al. Cooperative study of surgical adjuvant chemotherapy for colorectal cancer (third report): five year results. Jpn J Cancer Chemother 1991;18:461-9. (in Japanese).
12. Ito K, Yamaguchi A, Miura K, Kato T, Baba S, Matsumoto S, et al. Prospective randomized trial of oral adjuvant therapy with 5-FU derivative carmofur (HCFU) for colorectal cancer: 5 years follow up. Tokai HCFU Study Group, Third Study of Colorectal Cancer. Proc ASCO 1996;15:24.
13. Colorectal Cancer Chemotherapy Study Group of Japan. Five year results of a randomized controlled triel of adjuvant chemotherapy for curatively resected colorectal carcinoma. Jpn J Clin Oncol 1995;25:91-103.
14. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PG, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
15. SAS Institute. SAS/STAT Software: Changes and Enhancements Through Release 6.11. SAS Institute, Cary, NC, 1996.
16. Mitomi T, Tsuchiya S, Iijima N and Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum. Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 1992;35:123-30.
17. Pezdur R. New agents in the treatment of colorectal carcinoma: tomudex, UFT and doxifluridine. Cancer Invest 1994;13(Suppl 1):28-29.
18. Decosse JJ. Are we doing better with large bowel cancer? N Engl J Med 1984;310:782-3.
19. Editorial. Adjuvant treatment of carcinoma of the rectum and colon. Lancet 1985;2:367-8.
20. Krook JE, Moertel CG, Gunderson LL, Wieand HS Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
21. Pazdur R, Rhodes V, Lassare Y, Bready B, Soo E, Ajani JA, et al. UFT plus leucovorin: a potentially effective oral regimen in colorectal carcinoma. Proc ASCO 1994;13:201.
22. Pazdur R, Lassare Y, Rhodes V, Ajani JA, Sugarman MS, Patt TZ, et al. Phase II trial of UFT plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994;12:2296-300.